Information for the public
Other NICE guidance referred to in this guideline
-
Preventing type 2 diabetes: population and community interventions (see www.nice.org.uk/guidance/PH35)
-
Medicines adherence (see www.nice.org.uk/guidance/CG76/PublicInfo)
-
Prevention of cardiovascular disease at population level (see www.nice.org.uk/guidance/PH25)
-
Alcohol-use disorders: preventing harmful drinking (see www.nice.org.uk/guidance/PH24)
-
Smoking cessation services (see www.nice.org.uk/guidance/PH10)
-
Depression in children and young people (see www.nice.org.uk/guidance/CG28/PublicInfo)
-
Ustekinumab for the treatment of adults with moderate to severe psoriasis (see www.nice.org.uk/guidance/TA180/PublicInfo)
-
Adalimumab for psoriasis (see www.nice.org.uk/guidance/TA146/PublicInfo)
-
Depression in adults with a chronic physical health problem (see www.nice.org.uk/guidance/CG91/PublicInfo)
-
Promoting physical activity for children and young people (see www.nice.org.uk/guidance/PH17)
-
Lipid modification (see www.nice.org.uk/guidance/CG67/PublicInfo)
-
Obesity (see www.nice.org.uk/guidance/CG43/PublicInfo)
-
Promoting physical activity in the workplace (see www.nice.org.uk/guidance/PH13)
-
Infliximab for psoriasis (see www.nice.org.uk/guidance/TA134/PublicInfo)
-
Four commonly used methods to increase physical activity (see www.nice.org.uk/guidance/PH2)
-
Etanercept and efalizumab for the treatment of psoriasis (see www.nice.org.uk/guidance/TA103/PublicInfo)